Andrew S. Boyer - 30 Jun 2023 Form 4 Insider Report for Amneal Pharmaceuticals, Inc. (AMRX)

Role: Executive Vice President
Signature: /s/ Chris Daly, Attorney-in-Fact
Issuer symbol: AMRX
Transactions as of: 30 Jun 2023
Net transactions value: -$35,870
Form type: 4
Filing time: 05 Jul 2023, 16:30:16 UTC
Previous filing: 07 Mar 2023
Next filing: 15 Aug 2023
SEC: View on sec.gov

Transactions Table

Type	Sym	Class	Transaction	Value $	Shares	Change %	* Price $	Shares After	Date	Ownership	Footnotes
transaction	AMRX	Class A Common Stock	Options Exercise		+23,095	+8.8%		285,612	30 Jun 2023	Direct	F1, F2
transaction	AMRX	Class A Common Stock	Tax liability	$35,870	-11,571	-4.1%	$3.10	274,041	30 Jun 2023	Direct	F3

Derivative Securities (e.g., puts, calls, warrants, options, convertible securities)

Type	Sym	Class	Transaction	Value $	Shares	Change %	* Price $	Shares After	Date	Underlying Class	Amount	Exercise Price	Ownership	Footnotes
transaction	AMRX	Restricted Stock Units	Options Exercise	$0	-23,095	-100%	$0.000000^*	0	30 Jun 2023	Class A Common Stock	23,095		Direct	F2, F4

* An asterisk sign (*) next to the price indicates that the price is likely invalid.

Explanation of Responses:

Id	Content
F1	Represents the gross number of shares of Class A Common Stock, par value $0.01 per share (the "Class A Common Stock") issuable to the reporting person in connection with the vesting of restricted stock units. The actual number of shares issued was reduced by the number of shares withheld to satisfy tax withholding obligations. See footnote 3.
F2	Each restricted stock unit represents a contingent right to receive one share of the Issuer's Class A Common Stock.
F3	Represents shares of Class A Common Stock withheld to satisfy tax withholding obligations relating to the vesting of restricted stock units.
F4	On August 1, 2020, the reporting person was granted 69,284 restricted stock units vesting in three equal installments beginning on June 30, 2021.